Orinda, CA, United States of America

Brian Berman

This inventor holds 1 USPTO granted patent. Top assignee: Baker Cummins Dermatologicals, Inc.. Active years: 1994.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 1994

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Brian Berman - Innovator in Fibrotic Disorder Treatment

Introduction

Brian Berman is a notable inventor based in Orinda, California. He has made significant contributions to the field of medical treatment, particularly in addressing fibrotic disorders. His innovative approach has led to the development of a unique method that utilizes interferons for therapeutic purposes.

Latest Patents

Berman holds a patent for a method of treating fibrotic disorders in humans. This novel method involves administering a sufficient quantity of a composition containing human alpha- or beta-interferon. The goal is to raise the total concentration of such interferon in the affected tissue area to about 10 to about 4 × 10^7 IU per cubic centimeter. The interferons used can be naturally derived or recombinant DNA-derived. The composition can be administered through any conventional method and may include any pharmaceutically acceptable, interferon-compatible vehicle.

Career Highlights

Brian Berman is associated with Baker Cummins Dermatologicals, Inc., where he continues to work on innovative solutions for dermatological issues. His expertise in the field has positioned him as a key player in the development of treatments for fibrotic disorders.

Collaborations

Berman collaborates with Matthew R. Duncan, who is also involved in the research and development of dermatological treatments. Their combined efforts contribute to advancing medical science in their area of expertise.

Conclusion

Brian Berman's work in developing a method for treating fibrotic disorders showcases his commitment to innovation in medical treatment. His contributions are paving the way for new therapeutic options in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…